

# *How New Guidelines Will Impact Clinical Practice?*

## *Aortic Valve Guidelines*

Fabien Praz, MD, Bern University Hospital, Switzerland



TRANSCATHETER  
CARDIOVASCULAR  
THERAPEUTICS®

# Disclosure of Relevant Financial Relationships

Within the prior 24 months, I have had a financial relationship with a company producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients:

**Nature of Financial Relationship**

Grant/Research Support







Travel expenses

**Ineligible Company**



Abbott Vascular

Edwards Lifesciences, Abbott Vascular, Medira, Siemens Healthineers and InQB8 Medical Technologies

# Aortic Regurgitation




# Imaging Assessment of Patients with Aortic Regurgitation



# Management of Aortic Regurgitation

Recommendations	Class	Level
AV surgery is recommended in symptomatic patients with severe AR regardless of LV function.	I	B
AV surgery is recommended in asymptomatic patients with severe AR and LVESD $>50$ mm or LVESDi $>25$ mm/m $^2$ [especially in patients with small body size (BSA $<1.68$ m $^2$ )] or resting LVEF $\leq 50\%$ .	I	B
AV surgery may be considered in asymptomatic patients with severe AR and LVESDi $>22$ mm/m $^2$ , <b>LVESVi <math>&gt;45</math> mL/m<math>^2</math></b> [especially in patients with small body size (BSA $<1.68$ m $^2$ )], or resting LVEF $\leq 55\%$ , if the surgical risk is low.	IIb	REV.





ESC EACTS

Implementation of a volume cut-off based echocardiography or cardiac MRI

# Mode of Intervention for Severe Aortic Regurgitation

Recommendations	Class	Level
AV repair should be considered in selected patients with severe AR at experienced centres, when durable results are expected.	IIa	B REV.
TAVI may be considered for the treatment of severe AR in symptomatic patients ineligible for surgery according to the Heart Team, if the anatomy is suitable.	IIb	B NEW




# Aortic Stenosis - Expansion of TAVR indication


# Mode of Intervention in Patients with Severe AS

irrespective of the surgical risk score


Recommendations	Class	Level
TAVI is recommended in patients $\geq 70$ years of age with tricuspid AV stenosis, if the anatomy is suitable.	I	A REV.
SAVR is recommended in patients $<70$ years of age, if the surgical risk is low.	I	B REV.
SAVR or TAVI are recommended for all remaining candidates for an aortic BHV according to Heart Team assessment.	I	B REV.




# Mode of Intervention in Patients with Severe AS



Recommendations	Class	Level
It is recommended that AV interventions are performed in Heart Valve Centres that report their local expertise and outcome data, have on-site interventional cardiology and cardiac surgical programmes, and a structured collaborative Heart Team.	I	C
It is recommended that the mode of intervention is based on Heart Team assessment of individual clinical, anatomical, and procedural characteristics, incorporating lifetime management considerations and estimated life expectancy.	I	C



# Mode of Intervention in Patients with Severe Aortic Stenosis



## Recommendations

TAVI may be considered for the treatment of severe BAV stenosis in patients at increased surgical risk, if the anatomy is suitable.

Class  
**IIb**

Level  
**B**

**NEW**



## Recommendations

Non-transfemoral TAVI should be considered in patients who are unsuitable for surgery and transfemoral access.

Class  
**IIa**

Level  
**B**

**REV.**


# **Earlier Treatment of Asymptomatic AS Patients**

# Intervention for Asymptomatic AS


Recommendations	Class	Level
Intervention is recommended in asymptomatic patients with severe AS and LVEF <50% without another cause.	I	B
Intervention should be considered in asymptomatic patients (confirmed by a normal exercise test, if feasible) with severe, high-gradient AS and LVEF $\geq 50\%$ as an alternative to close active surveillance, if the procedural risk is low.	IIa	A
Intervention should be considered in asymptomatic patients with severe AS and LVEF $\geq 50\%$ if the procedural risk is low and one of the following parameters is present: <ul style="list-style-type: none"><li>Very severe AS (mean gradient <math>\geq 60</math> mmHg or <math>V_{max} &gt; 5.0</math> m/s)</li><li>Severe valve calcification (ideally assessed by CCT) and <math>V_{max}</math> progression <math>\geq 0.3</math> m/s/year.</li><li>Markedly elevated BNP/NT-proBNP levels (more than three times age- and sex-corrected normal range, confirmed on repeated measurement without other explanation).</li><li>LVEF &lt;55% without another cause.</li></ul>	IIa	B
Intervention should be considered in asymptomatic patients with severe AS and a sustained fall in BP ( $> 20$ mmHg) during exercise testing.	IIa	C

NEW

# RCTs in Patients With Asymptomatic Severe Aortic Stenosis




Génereux et al. N Engl J Med 2025;392:217-27




Loganathan et al. JAMA 2025;333(3):213-221

# RCTs in Patients With Asymptomatic Severe Aortic Stenosis




Banovic et al. Circulation. 2022;145:648–658.



Kang et al. N Engl J Med 2020;382:111-9.

# Limitations of RCTs in Asymptomatic Aortic Stenosis

- ✓ For some of them **small and underpowered**
- ✓ Inclusion of a **selected population of young low risk patients** with **very severe aortic stenosis**
- ✓ Quality of close surveillance in the conservative arm?
- ✓ Inclusion of TAVR implantation as an event in **EARLY-TAVR**




**Shared decision-making!**

ESC EACTS

# Bicuspid Aortic Stenosis

# Bicuspid Aortic Stenosis



## Recommendations


TAVI may be considered for the treatment of severe BAV stenosis in patients at increased surgical risk, if the anatomy is suitable.

Class	Level
IIb	B

NEW

## Potential risks of TAVR

- ↑ **Stroke**
- ↑ **Annular rupture**
- ↑ **Pravalvular leak**



# Take-home Messages

- Consider **volume** (*ideally by CMR*) and **modality of treatment** for **aortic regurgitation** (*Surgery vs. TAVR*)
- General trend of **expansion of TAVR indication** (*be reasonable and consider the evidence!*)
- Wide open door for **earlier intervention in patients with asymptomatic AS** (*as a shared decision with the informed patient!*)
- Specific recommendation for **bicuspid aortic stenosis** (*additional randomized evidence is needed*)